Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Adolfo de la Fuente Burguera"'
Autor:
Yu-Hung Wang, Adrián Mosquera Orgueira, Chien-Chin Lin, Chi-Yuan Yao, Min-Yen Lo, Cheng-Hong Tsai, Adolfo de la Fuente Burguera, Hsin-An Hou, Wen-Chien Chou, Hwei-Fang Tien
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract The European Leukemia Net recommendations provide valuable guidance in treatment decisions of patients with acute myeloid leukemia (AML). However, the genetic complexity and heterogeneity of AML are not fully covered, notwithstanding that ge
Externí odkaz:
https://doaj.org/article/6ead356802e74eccaafc335f241b2a39
Autor:
Teresa Bernal, Ainhoa Fernández Moreno, Almudena de LaIglesia, Celina Benavente, Ana García‐Noblejas, Daniel García Belmonte, Rosalía Riaza, Olga Salamero, Maria Angeles Foncillas, Alicia Roldán, Víctor Noriega Concepción, Laura Llorente González, Juan Miguel Bergua Burgués, Soraya Lorente de Uña, Gabriela Rodríguez‐Macías, Adolfo de la Fuente Burguera, Maria José García Pérez, Jose Luis López‐Lorenzo, Pilar Martínez, Concepción Aláez, Marta Callejas, Carmen Martínez‐Chamorro, José Rifón Roca, Lourdes Amador Barciela, Armando V. Mena Durán, Karoll Gómez Correcha, Esperanza Lavilla Rubira, María Luz Amigo, Ferran Vall‐llovera, Ana Garrido, María García‐Fortes, Dunia de Miguel Llorente, Anastasia Aules Leonardo, Carlos Cervero, Rosa Coll Jordá, Manuel M. Pérez‐Encinas, Marta Polo Zarzuela, Angela Figuera, Guillermo Rad, David Martínez‐Cuadrón, Pau Montesinos
Publikováno v:
Cancer Medicine, Vol 12, Iss 14, Pp 14892-14901 (2023)
Abstract Background CPX‐351 is approved for the treatment of therapy related acute myeloid leukemia (t‐AML) and AML with myelodysplastic related changes (MRC‐AML). The benefits of this treatment over standard chemotherapy has not been addressed
Externí odkaz:
https://doaj.org/article/9c1db4405e274742a000602740ddeff0
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, Mónica López Riñón, Claudio Cerchione, Adolfo de la Fuente Burguera, Marta Sonia González Pérez, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/5b644d52caf6407c83da3785ab40f5bd
Autor:
Emilie Bérard, Christoph Röllig, Sarah Bertoli, Arnaud Pigneux, Suzanne Tavitian, Michael Kramer, Hubert Serve, Martin Bornhäuser, Uwe Platzbecker, Carsten Müller-Tidow, Claudia D. Baldus, David Martínez-Cuadrón, Josefina Serrano, Pilar Martínez-Sánchez, Eduardo Rodríguez Arbolí, Cristina Gil, Juan Bergua, Teresa Bernal, Adolfo de la Fuente Burguera, Eric Delabesse, Audrey Bidet, Pierre-Yves Dumas, Pau Montesinos, Christian Récher
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 7, Pp 1-8 (2022)
Abstract In a context of therapeutic revolution in older adults with AML, it is becoming increasingly important to select patients for the various treatment options by taking account of short-term efficacy and toxicity as well as long-term survival.
Externí odkaz:
https://doaj.org/article/a79de68b14424fe89380e50d0b454990
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, Mónica López Riñón, Claudio Cerchione, Adolfo de la Fuente Burguera, Marta Sonia González Pérez, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Risk stratification in acute myeloid leukemia (AML) has been extensively improved thanks to the incorporation of recurrent cytogenomic alterations into risk stratification guidelines. However, mortality rates among fit patients assigned to low or int
Externí odkaz:
https://doaj.org/article/5aede6c8b7c54ba38df284fa7e1db4fd
Autor:
Alessandro Isidori, Claudio Cerchione, Naval Daver, Courtney DiNardo, Guillermo Garcia-Manero, Marina Konopleva, Elias Jabbour, Farhad Ravandi, Tapan Kadia, Adolfo de la Fuente Burguera, Alessandra Romano, Federica Loscocco, Giuseppe Visani, Giovanni Martinelli, Hagop Kantarjian, Antonio Curti
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
In the past few years, our improved knowledge of acute myeloid leukemia (AML) pathogenesis has led to the accelerated discovery of new drugs and the development of innovative therapeutic approaches. The role of the immune system in AML development, g
Externí odkaz:
https://doaj.org/article/a6e56f3f011e4e9596bb57c9ced75c4c
Autor:
Teresa Bernal, Ainhoa Fernández Moreno, Almudena de LaIglesia, Celina Benavente, Ana García‐Noblejas, Daniel García Belmonte, Rosalía Riaza, Olga Salamero, Maria Angeles Foncillas, Alicia Roldán, Víctor Noriega Concepción, Laura Llorente González, Juan Miguel Bergua Burgués, Soraya Lorente de Uña, Gabriela Rodríguez‐Macías, Adolfo de la Fuente Burguera, Maria José García Pérez, Jose Luis López‐Lorenzo, Pilar Martínez, Concepción Aláez, Marta Callejas, Carmen Martínez‐Chamorro, José Rifón Roca, Lourdes Amador Barciela, Armando V. Mena Durán, Karoll Gómez Correcha, Esperanza Lavilla Rubira, María Luz Amigo, Ferran Vall‐llovera, Ana Garrido, María García‐Fortes, Dunia de Miguel Llorente, Anastasia Aules Leonardo, Carlos Cervero, Rosa Coll Jordá, Manuel M. Pérez‐Encinas, Marta Polo Zarzuela, Angela Figuera, Guillermo Rad, David Martínez‐Cuadrón, Pau Montesinos
Publikováno v:
Cancer Medicine.
Background CPX-351 is approved for the treatment of therapy related acute myeloid leukemia (t-AML) and AML with myelodysplastic related changes (MRC-AML). The benefits of this treatment over standard chemotherapy has not been addressed in well matche
Autor:
Gail J. Roboz, Karen Yee, Amit Verma, Gautam Borthakur, Adolfo de la Fuente Burguera, Guillermo Sanz, Helai P. Mohammad, Ryan G. Kruger, Natalie O. Karpinich, Geraldine Ferron-Brady, Andre Acusta, Heather Del Buono, Therese Collingwood, Marc Ballas, Arindam Dhar, Andrew H. Wei
Publikováno v:
Leukemia & Lymphoma. 63:463-467
Autor:
Audrey Bidet, Hubert Serve, Pierre-Yves Dumas, Carsten Müller-Tidow, Josefina Serrano, Teresa Bernal, Sarah Bertoli, Juan Bergua, Eduardo Rodriguez Arbolí, Uwe Platzbecker, Pilar Martínez-Sánchez, Martin Bornhäuser, Eric Delabesse, Adolfo de la Fuente Burguera, Christian Recher, Arnaud Pigneux, Michael Kramer, Claudia D. Baldus, David Martínez-Cuadrón, Pau Montesinos, Emilie Bérard, Cristina Gil, Christoph Röllig, Suzanne Tavitian
Publikováno v:
Leukemia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
LEUKEMIA
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
LEUKEMIA
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric Europ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c4fd2308cc3bead0a723ebfdc6b70e7
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15187
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15187
Autor:
Courtney D. DiNardo, Alessandra Romano, Giuseppe Visani, Naval Daver, Guillermo Garcia-Manero, Giovanni Martinelli, Alessandro Isidori, Antonio Curti, Elias Jabbour, Hagop M. Kantarjian, Adolfo de la Fuente Burguera, Farhad Ravandi, Federica Loscocco, Claudio Cerchione, Tapan M. Kadia, Marina Konopleva
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
In the past few years, our improved knowledge of acute myeloid leukemia (AML) pathogenesis has led to the accelerated discovery of new drugs and the development of innovative therapeutic approaches. The role of the immune system in AML development, g